<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Morrison MS</submitter><funding>BU-CTSI</funding><funding>NCATS NIH HHS</funding><funding>European Union&amp;apos;s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie</funding><funding>NIA NIH HHS</funding><funding>Alzheimer’s Association 2021 Zenith Award</funding><funding>European Union Joint Program for Neurodegenerative Disorders</funding><funding>Swedish government and the County Councils</funding><funding>BrightFocus Foundation</funding><funding>Alzheimer Drug Discovery Foundation</funding><funding>National Institutes of Health</funding><funding>Swedish Research Council</funding><funding>Hjärnfonden, Sweden</funding><funding>Gun and Bertil Stohnes Foundation</funding><funding>Olav Thon Foundation</funding><funding>Anna Lisa and Brother Björnsson’s Foundation</funding><funding>Agneta Prytz-Folkes &amp;amp; Gösta Folkes Foundation</funding><funding>European Research Council</funding><funding>Erling-Persson Family Foundation</funding><funding>NINDS NIH HHS</funding><funding>Alzheimer’s Association Research</funding><funding>Swedish Parkinson Foundation</funding><funding>Gamla Tjänarinnor Foundation</funding><funding>NIA</funding><funding>Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation</funding><funding>Swedish Brain Foundation</funding><funding>Swedish Alzheimer Foundation</funding><funding>American Academy of Neurology Career Development Award, Alzheimer’s Association</funding><funding>CSRD VA</funding><funding>NINDS</funding><funding>Swedish Dementia Foundation</funding><funding>International Society for Neurochemistry’s</funding><funding>Stiftelsen för Gamla Tjänarinnor</funding><funding>United States Department of Veterans Affairs</funding><funding>UK Dementia Research Institute at UCL</funding><funding>AD Strategic Fund and the Alzheimer‘s Association</funding><funding>Veterans Affairs Merit Award</funding><funding>Swedish State Support for Clinical Research</funding><pagination>3546-3557</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10233293</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>145(10)</volume><pubmed_abstract>Blood-based biomarkers such as tau phosphorylated at threonine 181 (phosphorylated-tau181) represent an accessible, cost-effective and scalable approach for the in vivo detection of Alzheimer's disease pathophysiology. Plasma-pathological correlation studies are needed to validate plasma phosphorylated-tau181 as an accurate and reliable biomarker of Alzheimer's disease neuropathological changes. This plasma-to-autopsy correlation study included participants from the Boston University Alzheimer's Disease Research Center who had a plasma sample analysed for phosphorylated-tau181 between 2008 and 2018 and donated their brain for neuropathological examination. Plasma phosphorelated-tau181 was measured with single molecule array technology. Of 103 participants, 62 (60.2%) had autopsy-confirmed </pubmed_abstract><journal>Brain : a journal of neurology</journal><pubmed_title>Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy.</pubmed_title><pmcid>PMC10233293</pmcid><funding_grant_id>AARGD-20-685362</funding_grant_id><funding_grant_id>2018-02532</funding_grant_id><funding_grant_id>ADSF-21-831377-C</funding_grant_id><funding_grant_id>K23NS102399</funding_grant_id><funding_grant_id>FO2019-0228</funding_grant_id><funding_grant_id>I01-CX001038</funding_grant_id><funding_grant_id>R56 AG062109</funding_grant_id><funding_grant_id>AG068753</funding_grant_id><funding_grant_id>CX001698</funding_grant_id><funding_grant_id>I01 CX001038</funding_grant_id><funding_grant_id>850325</funding_grant_id><funding_grant_id>K23 NS102399</funding_grant_id><funding_grant_id>AF-930627</funding_grant_id><funding_grant_id>AG072978</funding_grant_id><funding_grant_id>U19 AG068753</funding_grant_id><funding_grant_id>L30 NS093634</funding_grant_id><funding_grant_id>ADSF-21-831381-C</funding_grant_id><funding_grant_id>AG063635</funding_grant_id><funding_grant_id>2017-00915</funding_grant_id><funding_grant_id>P30AG072978</funding_grant_id><funding_grant_id>FO2020-0240</funding_grant_id><funding_grant_id>201809-2016862</funding_grant_id><funding_grant_id>U54NS115266</funding_grant_id><funding_grant_id>860197</funding_grant_id><funding_grant_id>IK2 CX002065</funding_grant_id><funding_grant_id>ALFGBG-715986</funding_grant_id><funding_grant_id>ADSF-21-831376-C</funding_grant_id><funding_grant_id>AG062109</funding_grant_id><funding_grant_id>JPND2021-00694</funding_grant_id><funding_grant_id>I01 CX001698</funding_grant_id><funding_grant_id>R01 AG068398</funding_grant_id><funding_grant_id>RDAPB-201809-2016615</funding_grant_id><funding_grant_id>681712</funding_grant_id><funding_grant_id>JPND2019-466-236</funding_grant_id><funding_grant_id>U54 NS115266</funding_grant_id><funding_grant_id>A2020812F</funding_grant_id><funding_grant_id>P30 AG072978</funding_grant_id><funding_grant_id>R01AG066524</funding_grant_id><funding_grant_id>FO2017-0243</funding_grant_id><funding_grant_id>1R01AG068398-01</funding_grant_id><funding_grant_id>ZEN-21-848495</funding_grant_id><funding_grant_id>UL1 TR001430</funding_grant_id><funding_grant_id>R01 NS017950</funding_grant_id><funding_grant_id>R44 AG063635</funding_grant_id><funding_grant_id>2020-00124</funding_grant_id><funding_grant_id>ALFGBG-720931</funding_grant_id><funding_grant_id>NS017950</funding_grant_id><funding_grant_id>1UL1TR001430</funding_grant_id><funding_grant_id>R01 AG066524</funding_grant_id><funding_grant_id>AF-742881</funding_grant_id><pubmed_authors>Morrison MS</pubmed_authors><pubmed_authors>Mez J</pubmed_authors><pubmed_authors>Goldstein LE</pubmed_authors><pubmed_authors>Kowall NW</pubmed_authors><pubmed_authors>Budson AE</pubmed_authors><pubmed_authors>Zetterberg H</pubmed_authors><pubmed_authors>Sugarman MA</pubmed_authors><pubmed_authors>McKee AC</pubmed_authors><pubmed_authors>Alosco ML</pubmed_authors><pubmed_authors>Frank B</pubmed_authors><pubmed_authors>Turk KW</pubmed_authors><pubmed_authors>Au R</pubmed_authors><pubmed_authors>Aparicio HJ</pubmed_authors><pubmed_authors>Jun GR</pubmed_authors><pubmed_authors>Palmisano JN</pubmed_authors><pubmed_authors>Qiu WQ</pubmed_authors><pubmed_authors>Stern RA</pubmed_authors><pubmed_authors>Martin B</pubmed_authors><pubmed_authors>Ashton NJ</pubmed_authors><pubmed_authors>Stein TD</pubmed_authors><pubmed_authors>Steinberg EG</pubmed_authors><pubmed_authors>Tripodis Y</pubmed_authors><pubmed_authors>Karikari TK</pubmed_authors><pubmed_authors>Blennow K</pubmed_authors><pubmed_authors>Killiany R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy.</name><description>Blood-based biomarkers such as tau phosphorylated at threonine 181 (phosphorylated-tau181) represent an accessible, cost-effective and scalable approach for the in vivo detection of Alzheimer's disease pathophysiology. Plasma-pathological correlation studies are needed to validate plasma phosphorylated-tau181 as an accurate and reliable biomarker of Alzheimer's disease neuropathological changes. This plasma-to-autopsy correlation study included participants from the Boston University Alzheimer's Disease Research Center who had a plasma sample analysed for phosphorylated-tau181 between 2008 and 2018 and donated their brain for neuropathological examination. Plasma phosphorelated-tau181 was measured with single molecule array technology. Of 103 participants, 62 (60.2%) had autopsy-confirmed </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-19T23:05:59.599Z</modification><creation>2025-04-19T23:05:59.599Z</creation></dates><accession>S-EPMC10233293</accession><cross_references><pubmed>35554506</pubmed><doi>10.1093/brain/awac175</doi></cross_references></HashMap>